...
首页> 外文期刊>Systematic Reviews >Evaluating progestogens for prevention of preterm birth international collaborative (EPPPIC) individual participant data (IPD) meta-analysis: protocol
【24h】

Evaluating progestogens for prevention of preterm birth international collaborative (EPPPIC) individual participant data (IPD) meta-analysis: protocol

机译:评估孕激素以预防早产国际合作(EPPPIC)个人参与者数据(IPD)荟萃分析:方案

获取原文
           

摘要

Preterm birth is the most common cause of death and harm to newborn babies. Babies that are born early may have difficulties at birth and experience health problems during early childhood. Despite extensive study, there is still uncertainty about the effectiveness of progestogen (medications that are similar to the natural hormone progesterone) in preventing or delaying preterm birth, and in improving birth outcomes. The Evaluating Progestogen for Prevention of Preterm birth International Collaborative (EPPPIC) project aims to reduce uncertainty about the specific conditions in which progestogen may (or may not) be effective in preventing or delaying preterm birth and improving birth outcomes. The design of the study involves international collaborative individual participant data meta-analysis comprising systematic review, re-analysis, and synthesis of trial datasets. Inclusion criteria are as follows: randomized controlled trials comparing progestogen versus placebo or non-intervention, or comparing different types of progestogen, in asymptomatic women at risk of preterm birth. Main outcomes are as follows; fetal/infant death, preterm birth or fetal death (<=37 weeks, <=34 weeks, <= 28 weeks), serious neonatal complications or fetal/infant death, neurosensory disability (measured at 18?months or later) or infant/child death, important maternal morbidity, or maternal death. In statistical methods, IPD will be synthesized across trials using meta-analysis. Both ‘two-stage’ models (where effect estimates are calculated for each trial and subsequently pooled in a meta-analysis) and ‘one-stage’ models (where all IPD from all trials are analyzed in one step, while accounting for the clustering of participants within trials) will be used. If sufficient suitable data are available, a network meta-analysis will compare all types of progesterone and routes of administration extending the one-stage models to include multiple treatment arms. EPPPIC is an international collaborative project being conducted by the forming EPPPIC group, which includes trial investigators, an international secretariat, and the research project team. Results, which are intended to contribute to improvements in maternal and child health, are expected to be publicly available in mid 2018. PROSPERO CRD42017068299
机译:早产是新生儿死亡和伤害的最常见原因。早产婴儿可能会在出生时遇到困难,并在儿童早期遇到健康问题。尽管进行了广泛的研究,但孕激素(与天然激素黄体酮相似的药物)在预防或延缓早产以及改善分娩结果方面的有效性仍存在不确定性。国际预防早产儿孕激素评估国际合作项目(EPPPIC)旨在减少有关孕激素可能(或可能不)有效预防或延缓早产并改善出生结局的具体条件的不确定性。该研究的设计涉及国际协作的个人参与者数据荟萃分析,包括系统评价,重新分析和试验数据集的综合。纳入标准如下:在有早产风险的无症状妇女中比较孕激素与安慰剂或不干预,或比较不同类型的孕激素的随机对照试验。主要结果如下;胎儿/婴儿死亡,早产或胎儿死亡(<= 37周,<= 34周,<= 28周),严重的新生儿并发症或胎儿/婴儿死亡,神经感觉残疾(在18个月或更晚时测量)或婴儿/儿童死亡,重要的产妇发病率或产妇死亡。在统计学方法中,IPD将使用荟萃分析在各个试验中进行综合。 “两阶段”模型(在其中对每个试验计算出疗效估计值,然后将其汇总到荟萃分析中)和“一阶段”模型(在一个步骤中分析所有试验的所有IPD,同时考虑了聚类)试验中的参与者)。如果有足够的合适数据可用,网络荟萃分析将比较所有类型的孕酮和给药途径,将一阶段模型扩展到包括多个治疗组。 EPPPIC是一个由组成EPPPIC的小组进行的国际合作项目,该小组包括试验研究人员,国际秘书处和研究项目团队。旨在改善母婴健康的研究结果有望在2018年中期公开发布。PROSPERO CRD42017068299

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号